VANCOUVER, Oct. 24 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today
announced that the University of Texas M. D. Anderson Cancer Center, following
Institutional Review Board (IRB) approval, has initiated treatment of its
first patient in the Company's ongoing Phase I clinical trial using PRX302 for
localized recurrent prostate cancer. M. D. Anderson joins the University of
Vermont and Scott & White Memorial Hospital, lead center in the trial, which
began treating patients in May 2006.
